These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 16920344)
81. STW 5 (Iberogast) reduces afferent sensitivity in the rat small intestine. Müller MH; Liu CY; Glatzle J; Weiser D; Kelber O; Enck P; Grundy D; Kreis ME Phytomedicine; 2006; 13 Suppl 5():100-6. PubMed ID: 16713220 [TBL] [Abstract][Full Text] [Related]
82. [Iberogast: a modern phytotherapeutic combined herbal drug for the treatment of functional disorders of the gastrointestinal tract (dyspepsia, irritable bowel syndrome)--from phytomedicine to "evidence based phytotherapy." A systematic review]. Saller R; Pfister-Hotz G; Iten F; Melzer J; Reichling J Forsch Komplementarmed Klass Naturheilkd; 2002 Dec; 9 Suppl 1():1-20. PubMed ID: 12618546 [TBL] [Abstract][Full Text] [Related]
83. [STW 5/Iberogast: multi-target-action for treatment of functional dyspepsia and irritable bowel syndrome]. Allescher HD; Wagner H Wien Med Wochenschr; 2007; 157(13-14):301-7. PubMed ID: 17704976 [TBL] [Abstract][Full Text] [Related]
84. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials. EFSA GMO Panel Working Group on Animal Feeding Trials Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408 [TBL] [Abstract][Full Text] [Related]
87. Ex vivo/in vitro absorption of STW 5 (Iberogast) and its extract components. Kelber O; Wittwer A; Lapke C; Kroll U; Weiser D; Okpanyi SN; Heilmann J Phytomedicine; 2006; 13 Suppl 5():107-13. PubMed ID: 16920344 [TBL] [Abstract][Full Text] [Related]
88. The active components and the pharmacological multi-target principle of STW 5 (Iberogast). Wegener T; Wagner H Phytomedicine; 2006; 13 Suppl 5():20-35. PubMed ID: 16926095 [TBL] [Abstract][Full Text] [Related]
89. Phytotherapy for functional dyspepsia: a review of the clinical evidence for the herbal preparation STW 5. Rösch W; Liebregts T; Gundermann KJ; Vinson B; Holtmann G Phytomedicine; 2006; 13 Suppl 5():114-21. PubMed ID: 16978851 [TBL] [Abstract][Full Text] [Related]
90. Pharmaceutical prerequisites for a multi-target therapy. Kroll U; Cordes C Phytomedicine; 2006; 13 Suppl 5():12-9. PubMed ID: 16857355 [TBL] [Abstract][Full Text] [Related]
91. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin. Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137 [TBL] [Abstract][Full Text] [Related]